---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-23-000062"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T14:51:49.349866+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Nurix reports positive Phase 1 data for BTK degraders NX-5948 and NX-2127 at ASH 2023

## Summary
- NX-5948: 3 partial responses in CLL (n=7); no DLTs or treatment-related SAEs across 50-450 mg doses.
- NX-2127: 2 complete responses in NHL (MCL, DLBCL); 40.7% ORR in CLL (n=27), up from 33% at ASH 2022.
- NX-2127 safety manageable: neutropenia dose-related, atrial fibrillation 11.1% (down from 17% prior).
- Dose escalation continues for both programs; more data expected in 2024.
- Company plans to develop NX-5948 broadly in CLL and other NHL indications.

## SEC filing metadata
- accession: 0001549595-23-000062
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000062/0001549595-23-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000062/nrix-20231211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-23-000062
- JSON: https://secwatch.observer/filing/0001549595-23-000062.json
- Plain text: https://secwatch.observer/filing/0001549595-23-000062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.